Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: A unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor

Molecular Endocrinology

Volumn 16, Issue 7, 2002, Pages 1696-1710

  Carsol, Jean Louis ^a   Gingras, Sébastien ^b   Simard, Jacques ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PROLACTIN; TRANSCRIPTION FACTOR; ANDROSTANOLONE; APOD PROTEIN, HUMAN; APOLIPOPROTEIN; APOLIPOPROTEIN D; CARRIER PROTEIN; DNA BINDING PROTEIN; GLYCOPROTEIN; MILK PROTEIN; PIP PROTEIN, HUMAN; STAT5 PROTEIN; STAT5A PROTEIN, HUMAN; STAT5B PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; DNA BINDING; GENE EXPRESSION REGULATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INDUCTION; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; REPORTER GENE; SIGNAL TRANSDUCTION; STIMULUS RESPONSE; TRANSACTIVATION; TRANSCRIPTION REGULATION; ANIMAL; BINDING SITE; BREAST TUMOR; CELL CULTURE; DNA FLANKING REGION; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PROMOTER REGION;

5' FLANKING REGION; ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS D; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CARRIER PROTEINS; CONSERVED SEQUENCE; DIHYDROTESTOSTERONE; DNA-BINDING PROTEINS; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MILK PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; PROLACTIN; PROMOTER REGIONS (GENETICS); RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 85047682437     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.16.7.0875     Document Type: Article

References (95)

1. JAK/Stat signaling by cytokine receptors
2. Stats and gene regulation
3. The role of Stats in transcriptional control and their impact on cellular function
4. Association of Stats with relatives and friends
5. β-casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor
6. Mammary gland-specific nuclear factor is present in lactating rodent and bovine mammary tissue and composed of a single polypeptide of 89 kDa
7. Prolactin-dependent activation of a tyrosine phosphorylated DNA binding factor in mouse mammary epithelial cells
8. Jaks and Stats: Biological implications
9. Stat structure and function in signaling
10. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue
11. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype
12. A single amino acid in the DNA binding regions of Stat5A and Stat5B confers distinct DNA binding specificities
13. A sequence of the CIS gene promoter interacts preferentially with two associated Stat5A dimers: A distinct biochemical difference between Stat5A and Stat5B
14. Stat5a is mandatory for adult mammary gland development and lactogenesis
15. Requirement of Stat5b for sexual dimorphism of body growth rates and liver gene expression
16. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses
17. Stat5b-deficient mice are growth hormone pulse-resistant. Role of Stat5b in sex-specific liver p450 expression
18. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
19. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
20. Steroid and nuclear receptors
21. Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells
22. Stat1 depends on transcriptional synergy with Sp1
23. Synergy between interferon-γ and tumor necrosis factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB
24. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling
25. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α
26. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response
27. p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6
28. Stat5b down-regulates peroxisome proliferator-activated receptor α transcription by inhibition of ligand-independent activation function region-1 trans-activation domain
29. Cross-talk between Janus kinase-signal transducer and activator of transcription (JAK-Stat) and peroxisome proliferator-activated receptor-α (PPARα) signaling pathways. Growth hormone inhibition of pparα transcriptional activity mediated by stat5b
30. 2 macroglobulin gene
31. Functional interactions between Stat5 and the glucocorticoid receptor
32. Characterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cells
33. Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional cooperation in the regulation of gene transcription
34. Promoter-dependent synergy between glucocorticoid receptor and Stat5 in the activation of β-casein gene transcription
35. Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family
36. Cross-talk between Stat5b and estrogen receptor-α and -β in mammary epithelial cells
37. Regulation of milk protein gene expression
38. Prolactin-inducible proteins in human breast cancer cells
39. Review of GCDFP-15. An apocrine marker protein
40. Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen
41. Identification of the major protein components in breast secretions from women with benign and malignant breast diseases
42. A novel aspartyl proteinase from apocrine epithelia and breast tumors
43. Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T-47D
44. Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells
45. Potent stimulatory effect of interleukin-1α on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells
46. Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells
47. The prolactin-inducible protein (PIP/GC-DFP-15) gene: Cloning, structure and regulation
48. Negative regulation of transcription in vitro by a glucocorticoid response element is mediated by a trans-acting factor
49. Expression from cloned cDNA of cell-surface secreted forms of the glycoprotein of vesicular stomatitis virus in eucaryotic cells
50. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: Role of Stat5 in proliferation
51. 694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription
52. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions
53. Naturally occurring dominant negative variants of Stat5
54. The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate
55. Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation
56. Functional characterisation of mutations in the ligand-binding domain of the androgen receptor gene in patients with androgen insensitivity syndrome
57. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1)
58. Stats in oncogenesis
59. Modulation of Stat signaling by Stat-interacting proteins
60. Transcriptional inhibition by Stat5. Differential activities at growth-related vs. differentiation-specific promoters
61. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: Evidence for differential steroid receptor response elements
62. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons
63. The role of prolactin and growth hormone in breast cancer
64. Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture
65. Effect of prolactin and estradiol on cell proliferation in the uterus and the MXT mouse mammary neoplasm
66. Treatment of breast cancer with testosterone propionate. A preliminary report
67. Fluoxymesterone therapy in treatment of advanced breast cancer
68. Testosterone propionate therapy of breast cancer
69. Calusterone (7β,17α-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer
70. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer
71. Combination hormonal therapy with tamoxifen plus fluoxymesterone vs. tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis
72. Specific binding of estradiol and dihydrotestosterone in human mammary cancers
73. Distribution, frequency and quantitative analysis of estrogen, progesterone, androgen and glucocorticoid receptors in human breast cancer
74. Androgen receptors in breast cancer
75. Androgen receptor activity in human breast cancer and its relationship with estrogen and progesterone receptor activity
76. 5α-reductases in human breast carcinoma: Possible modulator of in situ androgenic actions
77. DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology
78. Androgens and breast cancer
79. Crucial role of cytokines in sex steroid formation in normal and tumoral tissues
80. Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat
81. Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts
82. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line
83. Androgen sensitivity of the new human breast cancer cell line MFM-223
84. Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells
85. Role of the cyclin-dependent kinase inhibitor p27Kip1 in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation
86. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice
87. Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16′α-chloro-3′,17β- dihydroxyestra-1′,3′,5′-(10′)triene-7′α -yl]undecanamide in human breast cancer ZR-75-1 cells
88. Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line
89. Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells
90. Gross cystic disease fluid protein-15 as a marker for breast cancer: Immunohistochemical analysis of 690 human neoplasms and comparison with α-lactalbumin
91. Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary
92. Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer
93. Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells
94. Potent inhibition of CD4/TCR-mediated T cell apoptosis by a CD4-binding glycoprotein secreted from breast tumor and seminal vesicle cells
95. 4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13